Meddenovo Drug Design
Latest round
- Series A
Last raised
- Jul 2024
Total raised
- $0.4M
Investors
- 1
About Meddenovo Drug Design
Founded in 2021 and based in Lyon, France, Meddenovo Drug Design operates as a provider of drugs using artificial intelligence technologies and molecular modeling. Ilke Ugur Marion (CEO) and Antoine MARION (CTO) are the co-founders of the company. The company specializing in accelerating pharmaceutical research and development using advanced computational biochemistry techniques. The firm focuses on rational drug design, particularly for cyclic peptides. Meddenovo aims to increase the efficiency of drug discovery by utilizing AI-supported tools, with the potential to reduce drug development costs by up to 30%. The company offers a range of services, including in silico testing of drug candidates, de novo drug design, and the generation of peptide databases tailored to specific therapeutic targets. The firm’s technology platform combines AI and physical computational approaches to support drug hunters in designing novel drug candidates. It integrates a comprehensive database of cyclic peptide-like medicines, offering unique software solutions for the development of peptide-based therapeutics.
Who invested in Meddenovo Drug Design
1 investor across 1 round
See all investors in Meddenovo Drug Design
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 26, 2024
Amount
$0.4M
Investors
Questions about Meddenovo Drug Design
Who invested in Meddenovo Drug Design?
Meddenovo Drug Design has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Meddenovo Drug Design raised?
Meddenovo Drug Design has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Meddenovo Drug Design last raise money?
Meddenovo Drug Design's most recent round on record is a Series A, in Jul 2024.
What does Meddenovo Drug Design do?
Founded in 2021 and based in Lyon, France, Meddenovo Drug Design operates as a provider of drugs using artificial intelligence technologies and molecular modeling.
Where is Meddenovo Drug Design headquartered?
Meddenovo Drug Design is headquartered in Lyon, France.
Which VCs invest in companies like Meddenovo Drug Design?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Meddenovo Drug Design's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Meddenovo Drug Design? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.